Compositions and methods comprising a combination of serotonergic drugs
This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.
1. A method of treating a psychological disorder comprising administering a dosage composition comprising a homogenous mixture of a first serotonergic drug and a purified psilocybin derivative selected from the group consisting of 3-(2-dimethylaminoethyl)-1H-indol-4-yl]dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl]dihydrogen phosphate, 4-hydroxy-N,N,N-trimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl]dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, and their salts to a subject in need thereof.
2. The method of claim 1 , wherein the first serotonergic drug comprises a Selective Serotonin Reuptake Inhibitor.
3. The method of claim 2 , wherein the Selective Serotonin Reuptake Inhibitor is 90-100% pure.
4. The method of claim 3 , wherein the Selective Serotonin Reuptake Inhibitor comprises escitalopram.
5. The method of claim 1 , wherein the purified psilocybin derivative is 3-(2-Dimethylaminoethyl)-1H-indol-4-yl]dihydrogen phosphate.
6. The method of claim 1 , wherein the purified psilocybin derivative is 4-hydroxy-N,N-dimethyltryptamine.
7. The method of claim 1 , wherein the dosage composition further comprises an excipient.
8. The method of claim 1 , wherein the first serotonerigic drug or the purified psilocybin derivative is in the form of a dried powder.
9. The method of claim 8 , wherein the purified psilocybin derivative is in crystalline form.
10. The method of claim 1 , wherein the purified psilocybin derivative is 90-100% pure.
11. The method of claim 8 , wherein the first serotonergic drug is a Selective Serotonin Reuptake Inhibitor in crystalline form.
12. The method of claim 1 , wherein the psychological disorder is chosen from an anxiety disorder, a compulsive disorder, addiction, and a depressive disorder.